News & Events:ALVR

AlloVir's Posoleucel Shows Early Safety In Kidney Transplant Recipients

Allovir Inc (ALVR): * ALLOVIR REPORTS BLINDED, PRELIMINARY, PHASE 2 DATA SUPPORTING THE ONGOING STUDY OF POSOLEUCEL, A MULTI-VIRUS-SPECIFIC T CELL THERAPY, FOR THE TREATMENT OF BK VIREMIA IN KIDNEY TRANSPLANT RECIPIENTS. * Allovir Inc (ALVR) - PHASE 2 STUDY COMPLETED ENROLLMENT AHEAD OF SCHEDULE. * Allovir Inc (ALVR) - POSOLEUCEL WELL-TOLERATED WITH NO CASES OF GRAFT REJECTION OBSERVED TO DATE.

Phase 2 study completed enrollment ahead of schedule Posoleucel well-tolerated with no cases of graft rejection observed to date Overall decline in median BK viral load among patients completing 12 weeks of dosing with posoleucel or placebo Posoleucel detected up to 12 weeks after last infusion Topline, unblinded study results from all 61 patients expected to be released in 1Q 2023 WALTHAM, Mass.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

90 Biggest Movers From Yesterday

58 Stocks Moving In Thursday's Mid-Day Session

  On Wednesday, 807 companies reached new 52-week lows. The following stocks created new 52-week lows on Wednesday: Be sure to stay with Benzinga for further updates and market-moving news.

  AlloVir reported its Q1 earnings results on Thursday, May 5, 2022 at 07:00 AM. Here's what investors need to know about the announcement. AlloVir beat estimated earnings by 13.75%, reporting an EPS of $-0.69 versus an estimate of $-0.8. Revenue was down $0.00 from the same period last year.

Allovir Inc (ALVR): * ALLOVIR REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS. * Q1 LOSS PER SHARE $0.69 Source text for Eikon: Further company coverage:

Initiated posoleucel registrational study to prevent six devastating viral infections and now enrolling high-risk allo-HCT patients in the U.S., Western Europe and Asia FDA granted RMAT designation to posoleucel for Phase 3 multi-virus prevention indication with an estimated annual addressable patient population of 40,000 allo-HCT patients Progressed enrollment in three Phase 3 studies for poso...

  This article was generated by Benzinga's automated content engine and reviewed by an editor.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

  On Monday, 721 companies achieved new lows for the year. During Monday, the following stocks set new 52-week lows: Be sure to stay with Benzinga for further updates and market-moving news.

  On Friday, 431 companies hit new 52-week lows. Here are all the stocks that set new 52-week lows on Friday: Be sure to stay with Benzinga for further updates and market-moving news.

U.S. stocks traded mixed toward the end of trading, with the Dow Jones climbing around 300 points on Wednesday. The Dow traded up 0.85% to 35,206.75 while the NASDAQ fell 0.96% to 13,488.42. The S&P also rose, gaining, 0.16% to 4,469.17. Also check this: 4 Stocks Under $5 Insiders Are Aggressively Buying Leading and Lagging Sectors Real estate shares jumped by 1.9% on Wednesday.

U.S. stocks traded mixed midway through trading, with the Nasdaq composite dropping more than 150 points on Wednesday. The Dow traded up 0.76% to 35,176.54 while the NASDAQ fell 1.17% to 13,460.26. The S&P also rose, gaining, 0.03% to 4,463.70. Also check this: 4 Stocks Under $5 Insiders Are Aggressively Buying Leading and Lagging Sectors Real estate shares jumped by 1.5% on Wednesday.

28 Stocks Moving In Wednesday's Mid-Day Session

U.S. stocks traded mixed this morning, with the Dow Jones gaining more than 250 points on Wednesday. Following the market opening Wednesday, the Dow traded up 0.76% to 35,176.49 while the NASDAQ fell 0.60% to 13,537.29. The S&P also rose, gaining, 0.21% to 4,471.63.